Cantor Fitzgerald reiterated their buy rating on shares of Agile Therapeutics (NASDAQ:AGRX) in a report issued on Monday, November 20th. Cantor Fitzgerald currently has a $8.00 price objective on the specialty pharmaceutical company’s stock.
A number of other equities analysts also recently commented on the stock. Royal Bank Of Canada lifted their price objective on shares of Agile Therapeutics from $8.00 to $10.00 and gave the stock an outperform rating in a report on Thursday, September 14th. HC Wainwright set a $10.00 price target on shares of Agile Therapeutics and gave the company a buy rating in a report on Thursday, October 12th. Janney Montgomery Scott restated a buy rating and set a $13.00 price objective on shares of Agile Therapeutics in a research note on Thursday, September 7th. ValuEngine cut shares of Agile Therapeutics from a sell rating to a strong sell rating in a research report on Friday, September 1st. Finally, Noble Financial restated a buy rating on shares of Agile Therapeutics in a report on Sunday, July 30th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $10.20.
Shares of Agile Therapeutics (NASDAQ:AGRX) traded down $0.32 during midday trading on Monday, reaching $4.56. 281,851 shares of the company were exchanged, compared to its average volume of 360,271. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $7.06. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.10 and a current ratio of 4.10.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03. equities research analysts expect that Agile Therapeutics will post -0.99 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Janney Montgomery Scott LLC bought a new stake in Agile Therapeutics in the second quarter valued at $122,000. Royal Bank of Canada grew its position in Agile Therapeutics by 608.0% in the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after acquiring an additional 27,907 shares during the period. OxFORD Asset Management LLP bought a new stake in Agile Therapeutics in the third quarter valued at $161,000. Susquehanna International Group LLP bought a new stake in Agile Therapeutics in the second quarter valued at $205,000. Finally, LMR Partners LLP bought a new stake in Agile Therapeutics in the second quarter valued at $211,000. Institutional investors and hedge funds own 72.96% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Cantor Fitzgerald Reaffirms “Buy” Rating for Agile Therapeutics (NASDAQ:AGRX)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/06/agile-therapeutics-inc-agrx-given-buy-rating-at-cantor-fitzgerald.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.